Collaboration is one of the cornerstones of the Lupus Research Alliance’s research philosophy. We strive to identify and engage partners across disciplines and sectors to accelerate foundational and translational research in lupus. We welcome new partnering opportunities. Please contact Teodora Staeva, Ph.D. (tstaeva@lupusresearch.org)
Industry
Current partnerships
Lupus Industry Council
The Lupus Research Alliance Lupus Industry Council (LIC) includes pharmaceutical and biotechnology companies working together in the pre-competitive space to address common impediments to drug development in lupus and accelerate the pace of bringing new lupus therapies to the market. Current collaborative working groups hosted by the LIC are Lupus Nephritis Urine Protein Biomarkers and Flare Prevention in Clinical Studies.
LRA-Genentech Research Partnership
The LRA has collaborated with Genentech, a member of the Roche Group, to establish the Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus (LGA-IRT) as a new funding mechanism to support the development and mechanistic understanding of safe and accessible immune resetting therapies for lupus patients.
Nonprofits
Bloomberg Philanthropies
Bloomberg Philanthropies has been a key partner to the Lupus Research Alliance for more than 10 years and generously has supported the mission of the Lupus Research Alliance. Initially focused on fundamental research and innovation, the partnership brought a broad group of leading scientists into lupus research and yielded significant findings and new targets for systemic lupus erythematosus (SLE).
The most recent iteration of the partnership launched the Lupus Research Alliance’s largest and most collaborative grant mechanism, the Global Team Science Award.
Breakthrough T1D—Lupus Research Alliance—National Multiple Sclerosis Society (NMSS) Partnership on Common Mechanisms of Autoimmunity
Breakthrough T1D (formerly JDRF), the Lupus Research Alliance, and the National Multiple Sclerosis Society have joined forces to identify common mechanisms of autoimmunity. These three leading autoimmune disease organizations are once again jointly funding research projects looking at common underlying disease mechanisms.
Visit the Common Mechanisms of Autoimmunity website to learn more about the initiative.
Government
Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership Program Autoimmune and Immune-Mediated Diseases (AMP AIM)
The Lupus Research Alliance is a partner in AMP AIM, which brings together nearly two dozen organizations from the public, private, and nonprofit sectors to accelerate the identification and validation of new therapeutic targets by reconstructing shared immune response pathways through spatial and multi-omics technologies. The project is managed by the FNIH and builds on the success of AMP RA/SLE in which LRA was also a partner.
Accelerating Medicines Partnership (AMP) Rheumatoid Arthritis (RA)/Lupus
The Lupus Research Alliance is a partner in the Accelerating Medicines Partnership Rheumatoid Arthritis (RA)/Lupus, which brings together the National Institutes of Health (NIH), industry and nonprofit organizations to identify new therapeutic pathways and targets in RA and lupus nephritis (LN). The project is generating groundbreaking results with potential to transform clinical care for LN.
Academia
Lupus Research Alliance Lupus Brain Bank: Lupus Research Alliance—Harvard Brain Tissue Resource Center (HBTRC) collaboration
The Lupus Research Alliance has partnered with the Harvard Brain Tissue Resource Center (HBTRC), one of six National Institutes of Health (NIH) NeuroBioBanks to establish the Lupus Research Alliance Lupus Brain Bank.
The generous gift of lupus patient donors and their families enables critical research on the neuropsychiatric manifestations of lupus.
